Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.20 -6.6%	$1.61	$1.18 ▼ $3.78	$261.35M	0.6	3.26 million shs	6.74 million shs
DYN Dyne Therapeutics	$9.40 -6.2%	$10.40	$6.36 ▼ $47.45	$1.07B	1.19	1.60 million shs	5.56 million shs
ETNB 89bio	$7.64 -1.5%	$7.30	$4.16 ▼ $11.84	$1.11B	1.23	1.35 million shs	1.30 million shs
SPRY ARS Pharmaceuticals	$13.49 -3.8%	$13.02	$7.55 ▼ $18.51	$1.32B	0.84	1.19 million shs	1.47 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	-6.64%	-28.87%	-16.43%	-25.31%	-58.93%
DYN Dyne Therapeutics	-6.65%	-20.27%	+25.50%	-43.91%	-63.35%
ETNB 89bio	-1.46%	-4.78%	+39.11%	-33.18%	-18.50%
SPRY ARS Pharmaceuticals	-3.78%	-3.44%	+5.14%	+5.39%	+42.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	3.3549 of 5 stars	3.5	3.0	3.4	4.2	0.6
DYN Dyne Therapeutics	3.3679 of 5 stars	4.5	1.0	3.5	4.2	0.0
ETNB 89bio	2.9775 of 5 stars	4.5	1.0	4.0	0.8	0.6
SPRY ARS Pharmaceuticals	3.029 of 5 stars	3.6	2.0	2.7	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.90	Moderate Buy	$9.29	677.31% Upside
DYN Dyne Therapeutics	3.07	Buy	$47.46	404.91% Upside
ETNB 89bio	3.00	Buy	$27.25	256.82% Upside
SPRY ARS Pharmaceuticals	3.17	Buy	$31.00	129.80% Upside

Current Analyst Ratings Breakdown

Latest ALLO, SPRY, DYN, and ETNB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/30/2025	ETNB 89bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/24/2025	ETNB 89bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
4/8/2025	ETNB 89bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
3/22/2025	ETNB 89bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
3/21/2025	DYN Dyne Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$18.00 ➝ $17.00
3/19/2025	ALLO Allogene Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $8.00
3/17/2025	DYN Dyne Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
3/17/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
3/14/2025	ALLO Allogene Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$10.00 ➝ $10.00
3/14/2025	ALLO Allogene Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
3/14/2025	ALLO Allogene Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$5.00

(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$22K	11,879.66	N/A	N/A	$3.04 per share	0.39
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$1.49 per share	N/A
ETNB 89bio	N/A	N/A	N/A	N/A	$5.75 per share	N/A
SPRY ARS Pharmaceuticals	$89.15M	14.86	N/A	N/A	$2.40 per share	5.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$327.27M	-$1.33	N/A	N/A	N/A	N/A	-52.13%	-41.29%	5/12/2025 (Estimated)
DYN Dyne Therapeutics	-$235.94M	-$3.35	N/A	N/A	N/A	N/A	-57.46%	-51.62%	5/8/2025 (Estimated)
ETNB 89bio	-$142.19M	-$3.38	N/A	N/A	N/A	N/A	-59.58%	-52.21%	5/8/2025 (Estimated)
SPRY ARS Pharmaceuticals	-$54.37M	$0.08	N/A	N/A	N/A	N/A	-22.56%	-21.82%	5/14/2025 (Estimated)

Latest ALLO, SPRY, DYN, and ETNB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	SPRY ARS Pharmaceuticals	-$0.35	N/A	N/A	N/A	$7.48 million	N/A
5/12/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	N/A	N/A	N/A	$0.00 million	N/A
5/8/2025	Q1 2025	DYN Dyne Therapeutics	-$0.88	N/A	N/A	N/A	N/A	N/A
5/1/2025	Q1 2025	ETNB 89bio	-$0.50	-$0.49	+$0.01	-$0.49	N/A	N/A
3/20/2025	Q4 2024	SPRY ARS Pharmaceuticals	-$0.04	$0.52	+$0.56	$0.52	$15.46 million	$86.58 million
3/13/2025	Q4 2024	ALLO Allogene Therapeutics	-$0.34	-$0.28	+$0.06	-$0.28	$0.01 million	N/A
3/6/2025	Q4 2024	ETNB 89bio	-$0.60	-$1.02	-$0.42	-$1.02	N/A	N/A
3/4/2025	Q4 2024	DYN Dyne Therapeutics	-$0.92	-$0.88	+$0.04	-$0.88	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
ETNB 89bio	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.35	9.35
DYN Dyne Therapeutics	N/A	17.02	17.02
ETNB 89bio	0.09	11.66	11.66
SPRY ARS Pharmaceuticals	N/A	12.56	12.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
DYN Dyne Therapeutics	96.68%
ETNB 89bio	N/A
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	24.30%
DYN Dyne Therapeutics	20.77%
ETNB 89bio	2.80%
SPRY ARS Pharmaceuticals	40.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	218.71 million	158.72 million	Optionable
DYN Dyne Therapeutics	100	113.63 million	80.63 million	Optionable
ETNB 89bio	40	145.98 million	103.15 million	Optionable
SPRY ARS Pharmaceuticals	90	98.21 million	58.21 million	Optionable

ALLO, SPRY, DYN, and ETNB Headlines

Recent News About These Companies

ARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

May 7 at 8:00 AM | globenewswire.com

Alyeska Investment Group L.P. Acquires 1,128,724 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

May 7 at 5:23 AM | marketbeat.com

Invesco Ltd. Reduces Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

May 6 at 3:22 AM | marketbeat.com

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results

May 5 at 8:00 AM | globenewswire.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by Marshall Wace LLP

May 5 at 3:36 AM | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Holdings Lifted by Barclays PLC

May 5 at 3:27 AM | marketbeat.com

ARS Pharmaceuticals Partners with ALK for Neffy Promotion

May 3, 2025 | investing.com

ALK Abello inks neffy co-promotion deal in USA

May 3, 2025 | thepharmaletter.com

ARS Pharmaceuticals (SPRY) Expected to Announce Quarterly Earnings on Thursday

May 3, 2025 | marketbeat.com

ARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffy

May 3, 2025 | msn.com

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

May 2, 2025 | globenewswire.com

Tower Research Capital LLC TRC Has $481,000 Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

May 2, 2025 | marketbeat.com

ARS Pharmaceuticals Has A Blockbuster Candidate

April 30, 2025 | seekingalpha.com

Brokerages Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Target Price at $31.00

April 30, 2025 | americanbankingnews.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Recommendation of "Buy" from Analysts

April 28, 2025 | marketbeat.com

Raymond James Financial Inc. Invests $6.58 Million in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

April 26, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by Trexquant Investment LP

April 15, 2025 | marketbeat.com

ExodusPoint Capital Management LP Buys Shares of 24,628 ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

April 15, 2025 | marketbeat.com

Vanguard Group Inc. Raises Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

April 15, 2025 | marketbeat.com

Laura Shawver Sells 50,002 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

April 10, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver Sells 50,002 Shares

April 9, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Is McDonald’s Stock Serving a Value Meal to Investors?
By Jeffrey Neal Johnson | April 13, 2025
View Is McDonald’s Stock Serving a Value Meal to Investors?
Medtronic: A Dividend Aristocrat With Stability and Innovation
By Jeffrey Neal Johnson | April 22, 2025
View Medtronic: A Dividend Aristocrat With Stability and Innovation
Wingstop Stock Jumps on Q1 Beat, Expansion Outlook
By Jeffrey Neal Johnson | May 4, 2025
View Wingstop Stock Jumps on Q1 Beat, Expansion Outlook
Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal
By Jeffrey Neal Johnson | April 22, 2025
View Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal
Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
By Leo Miller | May 6, 2025
View Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?

ALLO, SPRY, DYN, and ETNB Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.20 -0.09 (-6.64%)

Closing price 05/7/2025 03:59 PM Eastern

Extended Trading

$1.20 +0.01 (+0.84%)

As of 05/7/2025 07:52 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Dyne Therapeutics NASDAQ:DYN

$9.40 -0.62 (-6.19%)

Closing price 05/7/2025 04:00 PM Eastern

Extended Trading

$9.76 +0.37 (+3.88%)

As of 05/7/2025 07:55 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

89bio NASDAQ:ETNB

$7.64 -0.11 (-1.46%)

Closing price 05/7/2025 03:59 PM Eastern

Extended Trading

$7.65 +0.01 (+0.17%)

As of 05/7/2025 05:42 PM Eastern

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

ARS Pharmaceuticals NASDAQ:SPRY

$13.49 -0.53 (-3.78%)

Closing price 05/7/2025 04:00 PM Eastern

Extended Trading

$13.50 +0.02 (+0.11%)

As of 05/7/2025 07:49 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time